Anatomical and Functional Outcomes of Vitrectomy with/without Intravitreal Methotrexate Infusion for Management of Proliferative Vitreoretinopathy Secondary to Rhegmatogenous Retinal Detachment

Table 3

MTX versus mean visual acuity in each subgroup and no MTX use versus mean visual acuity in control.

		Final BCVA					value
		Mean	SD	Median	Minimum	Maximum
Subgroups based on MTX indication	Control 1	0.04	0.04	0.03	0.001	0.13	0.07
	Established PVR	0.11	0.15	0.05	0.01	0.7
	Control 2	0.08	0.06	0.1	0.001	0.2	0.03
	High-risk PVR	0.15	0.12	0.16	0.01	0.4
	Control 3	0.08	0.05	0.1	0.001	0.16	0.03
	No risk of PVR	0.16	0.14	0.16	0.01	0.5

BCVA, best-corrected visual acuity; MTX, methotrexate; PVR, proliferative vitreoretinopathy; SD, standard deviation. is significant at <0.05.